` ONVO (Organovo Holdings Inc) vs S&P 500 Comparison - Alpha Spread

ONVO
vs
S&P 500

Over the past 12 months, ONVO has underperformed S&P 500, delivering a return of -81% compared to the S&P 500's 9% growth.

Stocks Performance
ONVO vs S&P 500

Loading
ONVO
S&P 500
Add Stock

Performance Gap
ONVO vs S&P 500

Performance Gap Between ONVO and GSPC
HIDDEN
Show

Performance By Year
ONVO vs S&P 500

Loading
ONVO
S&P 500
Add Stock

Competitors Performance
Organovo Holdings Inc vs Peers

S&P 500
ONVO
ABBV
AMGN
GILD
VRTX
Add Stock

Organovo Holdings Inc
Glance View

Market Cap
3.2m USD
Industry
Biotechnology

Organovo Holdings, Inc. engages in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 7 full-time employees. The company went IPO on 2013-08-02. The firm is focused on building high fidelity, three-dimensional (3D) tissues that recapitulate key aspects of human disease. The firm is targeting the intestine and has ongoing 3D tissue developments in Ulcerative colitis (UC) and Crohn's disease (CD). The firm uses its platform technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. NovoGen Bioprinters can dispense pure hydrogel formulations and also serve as important components of company's tissue prototyping and manufacturing platform. The firm also intends to use its bioprinting platform as well as 3D technologies to treat its target diseases.

ONVO Intrinsic Value
HIDDEN
Show
Back to Top